Indications of Afatinib

1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer 

Afatinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by  an FDA-approved test.

Limitations of Use:

The safety and efficacy of Afatinib have not been established in patients whose tumors  have resistant EGFR mutations.

2 Previously Treated, Metastatic Squamous NSCLC 

Afatinib is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.

from FDA，2022.04